6 completed, 3 recruiting, 1 not yet recruiting. 10 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Recruiting 3, Not yet recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Completed 1 |
Follow Paresthesia: new trials by email Literature Review of Paresthesia trials Research Report on Paresthesia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control Trial Herbal Formulation, Shekar's appliance, Multivitamin/Mineral supplements - Oral and Maxillofacial Conditions | Phase 2 | Not yet recruiting | Dow University of Health Sciences | 20 | 2026-11-15 | 2026-11-06 |
| Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) VMD-3866 Gel, Placebo Gel - Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain | Phase 2 | Recruiting | VM Therapeutics LLC | 16 | 2025-12-12 | 2026-10-21 |
| Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-18 |
| Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-25 |
| Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children Midazolam, Lidocaine-Midazolam, Placebo - Burning Nose | Phase 2 / Phase 3 | Completed | Latakia University | 63 | 2017-06-01 | 2018-11-05 |
| ST266 in UV-induced Inflammation ST266 immediate, ST266 delayed - Skin Burns | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 10 | 2015-03-01 | 2019-05-15 |
| Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. incobotulinumtoxinA, Placebo - Restless Leg Syndrome | Phase 2 | Completed | Yale University | 24 | 2012-09-01 | 2016-03-21 |
| Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline) - Painful Diabetic Neuropathies | Phase 2 | Completed | Helixmith Co., Ltd. | 104 | 2012-08-01 | 2025-10-06 |
| Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection PP4001, Placebo - Urinary Tract Infection | Phase 2 | Completed | Pinnacle Pharmaceuticals, Inc. | 261 | 2011-07-01 | 2011-10-19 |
| Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy Fluoride varnish, Oral Hygiene, CPP-ACP - Mucositis, Dry Mouth | Phase 2 | Completed | Azad University of Medical Sciences | 30 | 2011-03-01 | 2012-11-29 |
Hypesthesia (4) · Anxiety Disorders (2) · Depression (2) · Neuralgia (2) · Pain (2) · Agnosia (1) · Cancer Pain (1) · Chronic Pain (1) · Diabetic Neuropathies (1) · Disease (1) · Dysuria (1) · Infections (1) · Mucositis (1) · Oral Submucous Fibrosis (1)
Nervous System Diseases (10) · Neurologic Manifestations (10) · Pathological Conditions, Signs and Symptoms (10) · Sensation Disorders (10) · Signs and Symptoms (10) · Somatosensory Disorders (10) · Mental Disorders (3) · Behavior (2) · Behavioral Symptoms (2) · Mouth Diseases (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Stomatognathic Diseases (2) · Diabetes Complications (1) · Diabetes Mellitus (1)
Oxygen (2) · Genetic Therapy (1) · Geritol (1) · Midazolam (1) · Oral Hygiene (1) · Saline Solution (1) · Toothbrushing (1) · casein phosphopeptide-amorphous calcium phosphate nanocomplex (1) · incobotulinumtoxinA (1)
Bernardino Clavo, MD, PhD (2) · Azad University of Medical Sciences (1) · Dow University of Health Sciences (1) · Helixmith Co., Ltd. (1) · Latakia University (1) · Noveome Biotherapeutics, formerly Stemnion (1) · Pinnacle Pharmaceuticals, Inc. (1) · VM Therapeutics LLC (1) · Yale University (1)
United States (3) · Spain (2) · Iran (1) · Pakistan (1) · South Korea (1) · Syria (1) · United Kingdom (1)
Bernardino Clavo, MD, PhD (2) · Bahman Jabbari, MD (1) · David L Steed, MD (1) · Elma D Baron, MD (1) · Himar Fabelo, BSc, PhD (1) · Jack Kessler, MD (1) · Jacob Lorenzo-Morales, Prof (1) · Nabih Raslan, Dr. (1) · Sepideh Banava, Assist-Prof (1) · Suma Krishnan (1) · Walaa Khalil, Dr. (1)